How often is it safe to have steroid knee injections?

After a steroid (cortisone) injection that settled knee pain for a few months, it is common to wonder whether it is safe to have another and how often this can be repeated. UK guidance does not set a single national numeric limit for steroid injections into the knee, but everyday UK practice is generally cautious: many services work to a pattern of no more than about 3–4 injections per year in the same knee, with at least 6–12 weeks between injections (and often fewer than that in reality).

In knee osteoarthritis, intra‑articular steroid injections are mainly a short‑term symptom tool, not a treatment that reverses arthritis. NICE’s NG226 includes intra‑articular corticosteroid injection as an option for osteoarthritis pain management, alongside exercise, weight management and other core measures. NHS information on hydrocortisone joint injections notes that pain and swelling relief typically lasts around 2 months, which is why steroids are often used for a flare, to make rehabilitation possible, or to get through a time‑limited goal such as a holiday or a work deadline.

Safety is usually about cumulative exposure rather than the single injection. NHS medicines information on steroids highlights dose‑ and duration‑related risks such as higher infection risk, bone thinning (osteoporosis), raised blood sugar, high blood pressure, mood changes and eye problems; even though a knee injection is local, repeated injections contribute to overall steroid exposure. NHS steroid‑injection guidance also notes typical short‑lived local side effects, and clinicians generally aim for the lowest effective dose for the shortest time.

There is also a knee‑specific “joint structure” concern with frequent, long‑term repeat injections into the same knee. Research has raised questions about cartilage effects with repeated intra‑articular steroid use; a 2017 JAMA trial of repeated triamcinolone injections is often cited in this context. That trial is not set out in the NHS/NICE patient information sources listed here, but it is one reason many knee clinicians avoid treating osteoarthritis as an indefinite cycle of injections every few months.

A practical point often used in clinic is that when knee relief is getting shorter than ~2 months, or when injections are being needed more often than every 3–4 months, it usually triggers a review of the overall plan (exercise/strength work, weight management, pain relief strategy, bracing, imaging, and—where appropriate—discussion of other injection types or surgical pathways). For editorial independence, this section stays with general UK safety guidance and does not include in‑body clinic booking prompts.

What are my main knee injection options and how do they differ?

Most knee injections used for osteoarthritis and other painful knee conditions sit on a spectrum from fast, short-term anti-inflammatory relief to slower, potentially longer symptom control. In UK practice they are usually delivered as an image‑guided outpatient injection (often ultrasound‑guided), and are generally used to reduce pain and swelling so that core knee care (for example strengthening and activity modification) is easier to do rather than being a stand‑alone plan (NHS osteoarthritis guidance).

A practical way to compare the main knee injection types

• Corticosteroid (“cortisone”): best thought of as the “calm the flare” injection when the knee is hot, swollen or very irritable. It is a potent anti‑inflammatory placed into the knee joint (sometimes with local anaesthetic) with an onset that is usually measured in days, and the benefit is typically short‑term (weeks to a few months) rather than persistent. NICE includes intra‑articular corticosteroid injection as a symptom‑management option in osteoarthritis.
• Hyaluronic acid (“knee gel”, viscosupplementation): aims to change the mechanics of the joint fluid — effectively a lubrication/cushioning approach rather than an anti‑inflammatory drug effect. Products vary from a single injection to 3–5 injection courses, and comparative evidence does not show a consistent advantage for longer multi‑injection regimens. Where it helps, private clinic information often frames the time‑course as months rather than weeks (commonly around the 6‑month mark), but NICE’s NG226 recommendation is clear that intra‑articular hyaluronan should not be offered for osteoarthritis because trials did not show meaningful improvements; NHS England’s 2023 knee‑OA decision aid also states hyaluronic acid injections do not help knee osteoarthritis.
• Platelet‑rich plasma (PRP): uses a small blood sample processed to concentrate platelets and growth factors, then injected back into the knee with the aim of modulating inflammation and supporting tissue homeostasis. Evidence summaries describe improvements in pain and function in knee osteoarthritis out to about 12 months in some studies, and some data suggest a short series (often around three injections) may be more durable than a single injection — but preparation methods vary, making results harder to compare. NICE’s interventional procedures guidance (IPG637/HTG497) positions PRP for knee OA as a procedure that should be used with special governance and outcome monitoring, rather than routine care.
• “Orthobiologic” and newer hydrogel options (for example polyacrylamide hydrogel such as Arthrosamid®): an umbrella that includes PRP as well as other injectables that aim to influence the joint environment rather than simply masking pain. Arthrosamid is described in UK private hospital information as a long‑acting, non‑biodegradable hydrogel injected into the knee for osteoarthritis symptoms; compared with standard “knee gel”, it is typically positioned as a single‑injection option with early studies reporting longer follow‑up, but the overall evidence base is less mature than for established steroid injections.

Later sections cover how these options map to NHS versus private access in Lincolnshire, what “repeat cycles” usually mean for gel‑type injections, and the practical cost ranges seen in UK clinics.

Can I get gel, PRP or biologic knee injections on the NHS?

NHS access for knee injections tends to come down to what is routinely funded locally for knee osteoarthritis (OA) and related knee inflammation. In England, NHS knee pathways usually start in general practice and then move into a community MSK service or hospital orthopaedics, depending on symptoms, examination and imaging.

Steroid injections: routinely available on the NHS NICE’s OA guideline NG226 includes intra‑articular corticosteroid injections as an option to manage osteoarthritis pain, so steroid injections are commonly available within NHS knee services when an injection is considered appropriate. In practical terms, this is the injection type most NHS patients are offered first for a painful, irritated knee.

Gel (hyaluronic acid): usually not offered for knee OA on the NHS For “knee gel” (hyaluronan / hyaluronic acid), NICE NG226 is explicit: “Do not offer intra‑articular hyaluronan injections to manage osteoarthritis.” NICE’s rationale notes that studies did not show meaningful improvements in pain, function or quality of life. NHS England’s 2023 knee‑OA decision aid echoes this in plain language, stating that hyaluronic acid injections do not help knee osteoarthritis. Local NHS funding rules often mirror this: for example, a Cheshire & Merseyside ICB policy classifies intra‑articular hyaluronan for osteoarthritic joint changes (including the knee) as not routinely commissioned.

PRP and other biologic injections: generally not routine NHS care NICE’s guidance on platelet‑rich plasma (PRP) for knee OA (IPG637 / HTG497) positions it as an interventional procedure that should be used only with special arrangements for governance, consent and outcome monitoring, rather than as standard OA care. Policies such as the Cheshire & Merseyside corticosteroid commissioning document also group PRP for knee OA with procedures that are not routinely commissioned, and NHS use is often seen in research settings (for example, an HRA‑listed study evaluating PRP + hyaluronic acid in knee OA).

Lincolnshire reality check: NHS first-line, private for choice and timing In Lincolnshire, NHS availability can vary by local ICB policy, but the national guidance above means that steroid injections are the most realistic NHS injection option, while gel, PRP and newer hydrogels (for example Arthrosamid®) are unlikely to be offered as standard NHS treatments for knee OA. Private self‑pay services in the county and nearby include Lincolnshire Knee Clinic (knee‑focused injections including PRP and Arthrosamid listed on its site) and PrivateGP Lincs (corticosteroid joint injections), alongside private hospital pathways such as The Lincoln Hospital.

Some patients mix pathways: an NHS diagnosis and rehabilitation plan may continue as normal, while a specific injection (such as PRP) is self‑funded privately for access or choice. Where this happens, continuity usually depends on clear sharing of the knee diagnosis, imaging reports and any injection record between providers.

Repeat knee gel injections when to book another cycle

After a first private “knee gel” (hyaluronic acid, HA) injection has helped, the next decision is usually about timing rather than simply “having it again”. In UK clinic information, a practical planning horizon for standard, resorbable HA is often around 6 months of symptom control on average, with some people getting less and others longer. This is a self‑pay discussion in most areas, because NICE’s NG226 rationale does not support HA for knee osteoarthritis in routine NHS care.

In private practice, repeat cycles are commonly arranged when symptoms return, rather than to a fixed calendar. A frequently quoted pattern is about every 6 months (roughly one to two courses per year), adjusted to what happened after the previous injection (for example, whether walking distance or stair comfort improved for several months, or only briefly). UK private pricing articles also reflect this “cycle” model, because the total cost depends on whether a product is a single‑shot injection or a multi‑injection course.

Evidence on repeat HA courses is reasonably reassuring but not definitive. A 2018 review by Altman et al. concluded that repeated courses of intra‑articular HA for knee OA appeared effective and safe, with repeat cycles maintaining or sometimes improving pain outcomes compared with the first course; however, published summaries do not define a clear “lifetime maximum” number of cycles, and long‑term scheduling still varies between clinicians.

Course length is also less clear‑cut than many marketing pages suggest. A systematic review discussed in an orthobiologics text found five‑injection HA regimens were not superior to three‑injection regimens for knee OA, and comparative evidence more broadly has not consistently shown that longer courses beat shorter‑course or single‑shot options. In practice, the choice often comes down to product type, convenience (for example, 1 appointment versus 3–5), and the overall treatment plan.

Where repeating may be rational despite mixed guideline support tends to be when there was a clear, measurable first response (for example, a return to regular 30‑minute walks over several months) and the goal is to support ongoing strengthening and load management. Red flags for repeating include:

• No meaningful benefit from the first cycle (for example, improvement lasting only days rather than months)
• A pattern of rapidly escalating pain and disability over a few months despite rehab progress
• The knee plan shifting towards a surgical pathway (for example, arthroplasty timing), where short‑term symptom cover may need a different discussion.

Longer‑acting, non‑resorbable hydrogels such as Arthrosamid® are presented differently: Imperial’s private hospital information describes it as a non‑biodegradable hydrogel injection for knee osteoarthritis, and UK patient guides cite studies reporting benefits out to at least 2 years in some cohorts. Because the material is designed to persist in the joint, the decision is usually framed as a bigger “one‑off” commitment than repeating standard HA.

In Lincolnshire (for example, Sleaford NG34 and Grantham NG31), repeat‑timing decisions are often made after a structured knee review—sometimes including imaging review, and occasionally objective measures such as gait markers (for example MAI Motion®)—so that a repeat injection is linked to functional goals rather than becoming an automatic 6‑month habit.

What do private knee injections cost in the UK and Lincolnshire?

When NHS-funded care is largely limited to a steroid knee injection, the practical next question is what self-pay “gel”, PRP or longer-acting hydrogel injections typically cost in Lincolnshire or similar UK regions. Published UK examples suggest there is no national tariff: clinics set their own fees, and totals can rise once consultation, ultrasound guidance, and imaging are added.

UK guide prices (per knee, per injection)

• Steroid (cortisone) injection: ~£120–£200 in one UK price guide, with some clinics listing ~£300 for a standard ultrasound-guided injection.
• Hyaluronic acid (HA, “knee gel”): ~£300–£850 per injection in a UK cost breakdown, with some packages or premium products reported up to ~£1,700. Another UK clinic price list starts HA from ~£350.
• PRP: a UK clinician-facing review gives an example self-pay cost of ~£450 per injection, and UK-wide self-pay pricing commonly falls into a ~£400–£700 bracket depending on provider and preparation.
• Long-acting hydrogel (e.g. Arthrosamid®/PAAG): one UK price list shows ~£2,250 per knee for a single injection.

A more useful budgeting model: “per course”, not just “per injection”

Costs often depend on whether the treatment is a single appointment or a planned series. Using the published per-injection bands above:

• A 3-injection HA course priced at £300–£850 per injection equates to ~£900–£2,550 for injection fees alone (before any consult/scan fees).
• A 3-injection PRP series at £400–£700 per injection equates to ~£1,200–£2,100 (again, excluding assessment/imaging).

Why the same injection can be priced very differently

Across the UK in 2023–2024 price examples, variation is commonly driven by:

• Product choice and formulation (brand, molecular weight, and whether it is marketed as “single-shot” versus weekly injections)
• Whether ultrasound guidance is included and who performs it
• What is bundled (follow-up review, physiotherapy, or a repeat assessment)
• Setting and clinician seniority (small MSK clinic versus private hospital pathway)
• Geography (London and some South-East markets often price higher than regional centres)

In Lincolnshire, private access exists locally through knee-focused and MSK providers (for example, Lincolnshire Knee Clinic lists injections including PRP and Arthrosamid, and PrivateGP Lincs lists corticosteroid joint injections), and private hospital self-pay pathways are also available (for example, The Lincoln Hospital publishes guide prices for orthopaedics). Lincolnshire Knee is part of the MSK Doctors group and offers consultant-led, ultrasound-guided knee injections, with exact fees confirmed at booking via lincolnshireknee.co.uk.

When should I stop repeating injections and consider other options?

Diminishing returns over time is a common knee-osteoarthritis dilemma: an injection that once bought 2–3 months of easier walking may later only deliver 3–4 weeks of partial relief. NICE’s NG226 and the NHS osteoarthritis information frame injections as an add‑on to core care (exercise/strengthening, weight management, pacing and simple analgesia), not as a stand‑alone long‑term strategy when day‑to‑day function keeps slipping.

Practical signs the injection cycle is no longer the main answer

Patterns that often trigger a “step back and reassess” moment include:

• Relief now lasting only days to a few weeks (for example, discomfort returning before the next month is out)
• Night pain or regular waking despite a recent injection
• Repeated functional losses such as struggling with stairs or walking to the shops despite ongoing injections
• Escalating stiffness over months (for example, the knee ‘seizing’ after sitting)
• Needing more than 3–4 steroid injections per year in the same knee area (a commonly quoted UK safety rule‑of‑thumb), or shortening the gaps below roughly 6–12 weeks

When these signs appear, endlessly rotating between steroid, gel, PRP or other biologic injections can become a form of delay rather than progress—especially if the underlying drivers have not been rechecked. A structured knee review typically looks again at things injections cannot “fix” on their own, such as the pattern of cartilage wear on imaging, varus/valgus alignment, meniscal tears, or ligament stability after an old injury.

In the 2023 NHS England knee‑OA decision aid, the pivot point is described in practical terms: when pain and function remain significantly impaired despite optimised non‑surgical care (and any appropriately used injections), it becomes reasonable to discuss more definitive options, including surgery such as partial or total knee replacement, rather than continuing indefinite injection cycles. Depending on the knee’s mechanics, an osteotomy may be part of that conversation in selected cases.

The key takeaway replaces a bare “book now” ending: injections can still be a useful bridge (to keep rehabilitation moving or to cover a flare), but once the bridge is repeatedly too short, the priority shifts to a whole‑knee plan that restores walking, stairs and sleep. Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral for consultant‑led assessment in Sleaford (NG34) and Grantham (NG31), with investigations that may include imaging review and objective gait measures when helpful.